We describe for first time overexpression of ErbB3 in Germ cell testicular tumors (GCTs). Moreover our results in vivo using an orthotopic model explain the complete lack of effect (refractoriness) to pure ErbB1 receptor inhibitors caused by an ErbB1-independent activation of ErbB2. In contrast, the dual inhibitor of ErbB1 and ErbB2 lapatinib is effective blocking tumor growth and could be a new alternative for treatment of those patients who are refractory to cisplatin (CDDP)-based chemotherapy.
ABSTRACT
In this work we have analyzed the expression of different members of the ErbB family in human samples of germ-cell testicular tumors (GCTs). We observed expression of ErbB1 or ErbB2 in different tumor subtypes, but we also found overexpression of ErbB3 in all GCTs tested. This pattern of expression was maintained when primary tumors were orthotopically implanted in nude mice.
We have chosen a choriocarcinoma model characterized by high levels of ErbB1, but also of ErbB2 and ErbB3, to assay the in vivo effect of ErbB inhibitors on tumoral growth. Our results showed a complete lack of effect (refractoriness) to the pure ErbB1 receptor inhibitors cetuximab and gefitinib.
While these inhibitors blocked ErbB1 phosphorylation, ErbB2 phosphorylation was not affected, suggesting an ErbB1-independent activation of this receptor.
In order to confirm the importance of ErbB2 activation, animals were treated with lapatinib, a dual ErbB1 and ErbB2 inhibitor. Lapatinib treatment caused a 50% inhibition in tumor growth, an effect correlated with a blockade of both ErbB1 and ErbB2 phosphorylation levels, and of downstream signalling pathways (Akt, ERKs and Stat3). ErbB2 activation could still occur due to the formation of ErbB2/ErbB3 heterodimers, and ErbB3 activation was completely inhibited by lapatinib. Our results explain why lapatinib but not anti-ErbB1 agents might be effective for treatment of GCT patients.
INTRODUCTION
The ErbB family of tyrosine kinase receptors includes ErbB1/EGFR, ErbB2/Neu/Her-2, ErbB3 and ErbB4. Ligand binding induces homo or heterodimerization between ErbB receptors, which leads to the activation of their intrinsic tyrosine kinase activity, autophosphorylation of intracellular tyrosine residues and activation of multiple signal transduction cascades 1, 2 .
ErbB2 lacks ligand-binding capacity, whereas ErbB3 is intrinsically inactive or at least, weakly active as a kinase 3 . Both of them heterodimerize with other ErbB family members to activate intracellular signalling 4 .
Altered ErbB signalling has been implicated in the development of different tumor types 5, 6 . Furthermore, in some studies ErbB1 or ErbB2 aberrant expression has been associated with a poor prognosis and resistance to conventional therapies 4, [7] [8] [9] . The implication of ErbBs in tumor progression has turned these receptors into some of the most studied molecular targets in clinical oncology. There are two main classes of ErbB receptor inhibitors:
monoclonal antibodies (mAbs) 10, 11 and small molecule tyrosine kinase inhibitors (TKIs) 4 . Targeted therapies against ErbBs have been successfully used in the treatment of some advanced breast, colorectal and non-small-cell lung cancers. FDA-approved drugs that inhibit ErbBs include two mAbs against ErbB1 (Cetuximab and Panitumumab), two mAbs against ErbB2 (trastuzumab or herceptin and pertuzumab); and four TKIs, two that specifically inhibit ErbB1 (Erlotinib, Gefitinib) and lapatinib that inhibits ErbB1 and ErbB2 9 .
Germ cell tumors (GCTs) of the testis are the most common solid malignant neoplasm in young adult males aged 15 to 40 years old, and represent the leading cause of cancer-related mortality and morbidity in this age group 12 . Testicular GCTs are divided into seminoma and non seminomatous germ cell tumors based on histological, biological, and clinical features. Non seminomatous GCTs include one or more of the following components:
teratoma, embryonal carcinoma, teratocarcinoma, yolk sac tumor and choriocarcinoma, the last one being the most aggressive component of mixed GCTs 13, 14 . ErbB1 and 2 expression seem to be restricted to non seminomatous germ cell tumors [14] [15] [16] , but the exact contribution of ErbBs in the development, differentiation and progression of these tumors is not known. Our results show that most GCTs express high levels of ErbB3. This ErbB3 expression explains tumor resistance to pure ErbB1 inhibitors, in contrast to positive effects of multiple ErbBs inhibition caused by lapatinib. GlaxoSmithKline. Both were dissolved in 0,5% carboxymethylcellulose -0,1%
MATERIALS AND METHODS

Chemical Compounds
Tween 80 (Sigma) solution.
Orthotopic implantation of testicular tumors
Male nu/nu Swiss mice were purchased from Harlan (Spain). For our studies several orthotopic testicular germ cell tumors models (TGTs) were used, originated from tumor patients: three embryonal carcinomas, two with heterogenous tumor histological compounds, one yolk sac and two choriocarcinomas, among them the TGT38. This last model and the surgical implantation methodology was previously described in Castillo-Avila et al 17 .
Treatment schedule
Treatments started when a palpable intra-abdominal mass was detected (14 days); studies were terminated when tumors in vehicle-treated animals were judged to adversely affect their well-being. Mice were sacrificed by CO 2 inhalation and the effects of the different treatments on tumor response were evaluated by determining tumor weight and volume, where
Volume=(length)(width 2 /2).
For the first treatment schedule five mice were treated with gefitinib, administered daily orally, for five consecutive days, at doses of 100 mg/kg. Four mice were treated with 1 mg cetuximab twice a week by intraperitoneal administration. As control group four mice received daily oral vehicle solution and intraperitoneal sterile serum at the same schedule as gefitinib and cetuximab mice. Mice were treated for 11 days.
For second treatment schedule, seven mice were treated with lapatinib 100 mg/kg administered daily orally. Nine mice were treated with vehicle oral solution with the same schedule as the lapatinib group. Mice were treated for 13 days.
None of these treatments had a significant effect on the body weight of mice, and animals appeared healthy and active throughout the duration of the study
Histological study
Representative fragments of the primary and xenografted tumors were fixed in buffered formalin, dehydrated and embedded in paraffin. Tissue sections (3-4 µm) were stained with hematoxylin-eosin for morphological analysis.
Anti-ErbB1 mouse monoclonal antibody (1:50) (ZYMED laboratories, 31G7), anti-ErbB2 mouse monoclonal antibody (1:100) (Novocastra, NCL-L-CB11) and anti-ErbB3 rabbit polyclonal antibody generated by Dr.Pandiella
(1:75) 18 were used for immunohistochemical characterization. Previous to primary antibody incubation, tissue sections were permeabilized with saponin, for ErbB1 staining, and with pepsin for ErbB2 staining. Slides were incubated with the secondary antibody anti-mouse (DAKO envision+ System-HRP), and the detection was done with the DAB+ Chromogen System (DAKO). The slides were then dehydrated and mounted.
OCT-frozen tissue sections from control and treated tumors were used for immunofluorescence staining carried out to detect Ki67 positive cells and apoptotic cells by TUNEL staining as described 17 .
Images of sections were obtained on an Olympus-BX60 microscope. To quantifiy Ki-67 and TUNEL staining six hotspot fields in viable tissue zones at x400 magnification were captured for each tumor. Quantification of staning areas was done using ImageJ software.
Western blotting
Western blot from samples from different treated tumors were performed as described 17 .
Blots were incubated with polyclonal rabbit anti-phospho tyrosine 1173 
Quantitative real-time PCR
Real-time PCR of cDNA obtained from TGT38 independent tumors and human testis was done as described 17 , with the exception of hErbB1 primers, where the annealing was carried out at 61ºC. Human specific primers used are 
Immunoprecipitation
To immunoprecipitate ErbB1 or ErbB2 and ErbB1-or ErbB2-associated proteins, TGT38 tumors were mechanically disrupted and lysed using RIPA lysis buffer as described. Tumor lysates, with 750 µg of total protein, were first precleaned by incubation for 4h at 4ºC on the orbital shaker with 60 µl of protein A-Sepharose beads (GE, Healtcare) and 60 µl of protein G-Sepharose beads (GE, Healtcare). Beads were then discarded after centrifugation, and lysates were incubated with 1,6 µg of the rabbit polyclonal anti-ErbB1 antibody (Santa Cruz) or 1,6 µg of the rabbit polyclonal anti-ErbB2 antibody Neu (sc18): SC-284 (Santa Cruz) over-night at 4ºC on the orbital shaker; with the exception of the negative controls, that were incubated without antibody. Then lysates were incubated for 6 h at 4ºC on the orbital shaker with 60µl of protein A-Sepharose beads (GE, Healtcare) and 60 µl of protein G-Sepharose beads (GE, Healtcare), previously cleaned with RIPA buffer. Immunoprecipitates were then collected by centrifugation, washed five times with RIPA buffer at 4ºC and denatured in SDS loading buffer for electrophoresis 2X. Then the immunoprecipitates were analysed by western blot as described previously.
Statistical analyses.
Statistical significance of differences in different parameters was determined using the Mann-Whitney U test. In all experiments, differences were considered statistically significant when p < 0.05.
RESULTS
Lack of effect of pure ErbB1 receptor inhibitors cetuximab and gefitinib on germ cell testicular growth
In order to assay the effect of inhibitors of ErbB1 on germ cell tumoral growth, first we evaluated the presence or absence of ErbB1 in different orthotopically-derived xenografted non seminoma testicular tumors in from different patients of nude mice (TGTs). We analyzed ErbB1 expression levels by western blot in samples from these TGTs, and were compared with ErbB expression in normal human testicle (Fig. 1A) . We detected high expression of ErbB1 in choriocarcinoma and in tumors formed by heterogenous compounds, as compared to levels expressed in normal human testicle. Lower levels of ErbB1 were present in embryonal carcinoma and yolk sac tumors. We also immunodetected presence or absence of ErbB2, that was also expressed at different levels in most of our GCT samples and their orthotopic-derived models.
We chose choriocarcinoma TGT38, an orthotopic tumor that expressed high levels of ErbB1 receptor, for our in vivo studies. We evaluated the effect of cetuximab, a monoclonal antibody anti-ErbB1, or gefitinib, a small molecule inhibitor of the tyrosine kinase activity of ErbB1, on the TGT38 tumor growth.
After tumor implantation we treated mice with these inhibitors, and at the end of the treatment tumor volume was measured. No effects on the choriocarcinoma tumoral growth were observed for any of the treatments (Fig. 1B) . We confirmed the lack of effect of cetuximab or gefitinib by measuring tumoral cell proliferation These results indicated a lack of effect of pure ErbB1 inhibitors on choriocarcinoma germ cell testicular tumor growth in our orthotopic model.
Cetuximab and gefitinib block ErbB1 but not ErbB2 phosphorylation
Given the lack of effect of ErbB1 inhibitors on choriocarcinoma growth, we then attempted to confirm the inhibitory effect of cetuximab or gefitinib on ErbB1 tyrosine kinase activity. We measured by western blot ErbB1 phosphorylation in tyrosine 1173, one of the main tyrosines autophosphorylated when ErbB1 is active 5, 20 . Our results showed that this tyrosine was phosphorylated in control tumors while, as expected, its phosphorylation level was clearly decreased by cetuximab treatment (52% inhibition) or by gefitinib treatment (80% inhibition), in the absence of any effect on total levels of ErbB1
( Fig. 2A and Sup. Fig. S1C ).
As is well known, ErbB1 receptor forms heterodimers with ErbB2, with cross phosphorylation and cross activation between receptors 4 . As our germ cell testicular TGT38 tumor model also express ErbB2 (Fig. 1A) , so we studied the effect of these inhibitors on ErbB2 phosphorylation. As is shown in Fig. 2B and Sup. 
Lapatinib, a dual ErbB1 and ErbB2 inhibitor, block choriocarcinoma tumoral growth
Taking into account the persistent ErbB2 activation, even in presence of cetuximab or gefitinib, we decided to assay a dual tyrosine kinase inhibitor for ErbB1 but also ErbB2, lapatinib 9 . We repeated the experiment performed with the pure ErbB1 inhibitors, this time treating mice with the dual ErbB1 and ErbB2
inhibitor. Lapatinib caused a 50% inhibition of tumoral volume growth (Fig 3A) ,
an effect correlated to a significant block of cell proliferation (80% decrease of Ki67 positive cells) and a significant increase in apoptosis (3.5 fold) ( Fig. 3B and   3C ).
Then, the expression levels of activated ErbB1 and ErbB2 were analysed in control and lapatinib treated tumors by western blotting. As expected, lapatinib caused a 95% decrease in levels of phospho-ErbB1 and an 80% decrease in levels of phospho-ErbB2 (Fig. 4A, 4B and 4C ). Using the same samples, we also measured levels of activation of downstream signalling pathways Akt, ERKs and Stat3 (Fig. 4D, 4E and 4F and Sup. Fig. S2B ).
Lapatinib significantly inhibited levels of phosphoAkt, phosphoERKs and phosphoStat3, in contrast with the lack of effect of cetuximab and gefitinib.
ErbB3 is overexpressed in germ cell testicular tumors
As indicated by our results, ErbB2 activity was normal in the absence of ErbB1 activity (Fig. 2) . As is well known, ErbB2 can also form heterodimers and become activated by other ErbB family receptors. Thus presence and activation of other ErbB receptors in these tumors could explain the ErbB2 maintained activity observed in our tumoral models treated with ErbB1-pure inhibitors. In order to confirm or discard this hypothesis, first we measured by RT-PCR mRNA levels for ErbB1, ErbB2, ErbB3 and ErbB4, comparing their levels in TGT38 tumors with levels in normal human testis. As shown in Fig. 5A , we detected overexpression of ErbB1 and ErbB2 mRNA levels in TGT38 as compared to normal testis. But more interesting, we detected an overexpression of ErbB3 mRNA levels, 16-fold higher than normal testicle levels. In contrast,
ErbB4 mRNA was not expressed in our choriocarcinoma tumor model. ErbB1, ErbB2 and ErbB3 overexpression were confirmed by western blot comparing independent TGT38 tumor samples to independent human testicle samples (Fig. 5B) .
Next, we analyzed ErbB3 and ErbB4 expression levels by western blot in samples from different TGTs orthotopically-derived models from different patients, and were compared with ErbBs expression in normal human testicle (Fig. 5C ). We found that ErbB3 was overexpressed in all non seminoma testicular tumoral models analyzed including choriocarcinomas, yolk sac, embryonal carcinoma or tumors formed by heterogenous compounds, as compared to normal testicle. In contrast, ErbB4 was expressed at similar levels to normal testicle in the different TGTs analyzed except in choriocarcinomas, were its expression was even lower than in normal testicle (Fig. 5C ).
In order to confirm the overexpression of ErbB3 in non seminoma 
ErbB3 activation depends on ErbB2 in germ cell testicular tumors
Taken account ErbB3 overexpression that we detected in GCTs, it is very likely then that ErbB3 would form heterodimers with ErbB2 in these tumor models. In order to show this was the case, we immunoprecipitated ErbB1 or ErbB2 from our samples and identified by western blot the members of the ErbB family that dimerize with these receptors (Fig. 6A and 6B ). Our results indicate very low levels of ErbB2 or ErbB3 in immunoprecipitates of ErbB1. In contrast,
while ErbB1 was present at very low levels in immunoprecipitated ErbB2, ErbB3 levels were high, suggesting that in our tumoral testicular model ErbB2 preferntially forms heterodimers with ErbB3.
Finally, we decided to analize the activation status of ErbB3 in TGT38 tumors after different treatments. First we examined phosphoErbB3 levels in control tumors and tumors treated with lapatinib, gefitinib or cetuximab. Our results indicated a complete block of ErbB3 activation with lapatinib treatment (Fig. 6C and 6D ), while in tumors treated with cetuximab or gefitinib phosphoErbB3 levels were not affected ( Fig. 6E and 6F ). These results suggested that in our tumoral model activation of ErbB3 depends on ErbB2 activation. In all, our results confirmed the existence of ErbB2/ErbB3 heterodimers and their capacity to signal.
DISCUSSION
In this work we have shown that pure ErbB1 inhibitors are not effective in a model of choriocarcinoma testicular tumor that overexpresses ErbB1, presumably due to maintained, ErbB1-independent ErbB2 activity. On the contrary, when activity of both receptors is blocked by the use of lapatinib, tumor growth is compromised. In the absence of ErbB1, ErbB2 can maintain its activity through the formation of active heterodimers with ErbB3. ErbB1 inhibitors also fail to block proliferation due to ErbB3 maintained activity 29 . In our case sustained ErbB2 activity explains the refractoriness of choriocarcinoma tumors to pure ErbB1 inhibitors.
ErbB2 lacks ligand-binding capacity and requires heterodimerization with other members of the family in order to be activated. In fact, due to its extracellular domain conformation, ErbB2 is the preferred partner and common subunit for the rest of ErbB members, and the more physiological dimers formed appear to be ErbB2-containing heterodimers 4, 30 . Specific inhibitors of ErbB1 also reduce ErbB2 signalling in breast cancer cells [31] [32] [33] Growth of these cells can be inhibited by lapatinib 47 , as is the case with our testicular tumor models. In contrast, lapatinib has no effect on lung cancer cells immunoprecipitates from TGT38 tumor lysates was carried out by western blot;
proteins were also analyzed in total tumor lysates (input). While low levels of 
